-
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both encouraging news and a...
IN THE SPOTLIGHT
-
Artificial Intelligence in Lung Cancer: Hope vs. Hype
Artificial intelligence (AI) is rapidly reshaping the future of cancer care, but such dramatic innovation also brings important questions. AI has evolved from early consumer tools... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting... -
Weekly Virtual Meetup
For patients/survivors - Join us every Tuesday at 12 pm ET for this general meetup for anyone impacted by lung cancer. After registering, you will receive a confirmation email... -
New Horizons in Immunotherapy: Lung Cancer Highlights from the 2025 SITC Meeting
The Society for Immunotherapy of Cancer (SITC) celebrated their 40th anniversary at their annual meeting in National Harbor, Maryland from November 5-9, 2025. The meeting focused... -
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
LUNGevity Foundation Invests $1.2 Million to Fuel Next Generation of Lung Cancer Research
LUNGevity Foundation announced $1.2 million in research awards that are designed to strengthen the lung cancer workforce and accelerate progress across the lung cancer continuum... -
New Accelerated Approval for HER2-positive NSCLC
On November 19, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sevabertinib (Hyrnuo®) to treat patients with locally-advanced or metastatic...
Cross-dataset adaptation of voxel-level deep radiomics for predicting survival in inoperable locally advanced NSCLC treated with immunotherapy
Cross-dataset adaptation of voxel-level deep radiomics for predicting survival in inoperable locally advanced NSCLC treated with immunotherapy
M2pep-modified liposomal nanoparticles delivering siITGB4 induce apoptosis and inhibit NSCLC metastasis via macrophage reprogramming
M2pep-modified liposomal nanoparticles delivering siITGB4 induce apoptosis and inhibit NSCLC metastasis via macrophage reprogramming
Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series
Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series
ASO Visual Abstract: Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC-A Systematic Review and Meta-analysis
ASO Visual Abstract: Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced PD-L1 ≥ 50% NSCLC-A Systematic Review and Meta-analysis
Original InvestigationIdentifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors
Original InvestigationIdentifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors
FDA Approves Hernexeos, the First Targeted Therapy for Adults with HER2-Mutant Advanced NSCLC as an Initial Treatment Option
FDA Approves Hernexeos, the First Targeted Therapy for Adults with HER2-Mutant Advanced NSCLC as an Initial Treatment Option
Synthekine and MSD collaborate for STK-012 combination trial to treat NSCLC
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
Engineered Spray-Dried PLGA-PEG Dual-Coated Micelles with Lactose/Trehalose Matrices for Pulmonary Doxorubicin Delivery: Achieving Sustained Release and Improved Aerosol Performance in NSCLC Therapy
Engineered Spray-Dried PLGA-PEG Dual-Coated Micelles with Lactose/Trehalose Matrices for Pulmonary Doxorubicin Delivery: Achieving Sustained Release and Improved Aerosol Performance in NSCLC Therapy